Results 151 to 160 of about 713,192 (254)

Isolating T‐Cell Potent Lentiviral Vector Subpopulations through Rational Design of Nanofiber Anion‐Exchange Adsorbents

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Generation of CAR‐T cell therapies relies predominantly on lentiviral vectors (LVs). As in vivo CAR‐T trials progress, demand for larger quantities of higher‐potency LV is expected. However, primary capture by anion‐exchange chromatography (AIEX) remains a major manufacturing bottleneck from use of adsorbents not tailored to LVs, leading to ...
George Pamenter, Gyorgy Ovari, Anurag Kulkarni, Thomas Williams‐Fegredo, Carol Knevelman, Kyriacos Mitrophanous, Lee Davies, Farzad Foroutan, Matthew Townsend, Stephen Goldrick, Daniel G. Bracewell   +10 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Clinical Outcomes of Drug‐Eluting Stents and Drug‐Coated Balloons in Tortuous Small Coronary Lesions

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In small, tortuous coronary lesions, the long‐term comparative performance of drug‐coated balloon (DCB) angioplasty versus drug‐eluting stent (DES) treatment remains uncertain, despite both strategies being widely used in contemporary percutaneous coronary intervention (PCI) practice. Aims This study aimed to compare 3‐year clinical
Shunichiro Ishio, Takashi Nagasaka, Ryota Taniuchi, Shiro Amanai, Yohei Ishibashi, Noriaki Takama, Hideki Ishii   +6 more
wiley   +1 more source

Apolipoprotein E Mimetic Peptide-Mediated Modulation of Lipid Homeostasis. [PDF]

Biomolecules
Patel DR, Martin CL, Anantharamaiah GM, Aller SG.   +3 more
europepmc   +1 more source

Clinical Impact of Adherence to Fractional Flow Reserve Guidance in Acute Coronary Syndrome

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Fractional flow reserve (FFR) is established to guide revascularization in stable coronary disease and non‐culprit lesions in acute coronary syndromes (ACS). However, real‐world adherence to FFR guidance across the spectrum of ACS presentations, including ambiguous culprit scenarios, remains incompletely characterized.
Eun Ho Choo, Ik Jun Choi, Sungmin Lim, Donggyu Moon, Dae‐Won Kim, Kiyuk Chang   +5 more
wiley   +1 more source

Could chimeric antigen receptor-T cell treatment of atherosclerosis in mice translate to a human therapy? [PDF]

Ann Transl Med
Gieseg S, Hock B, Ogugofor M, McCormick S.   +3 more
europepmc   +1 more source

Five‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and
Yangyoun Lee, Hong‐Seok Lim, Kyoung‐Woo Seo, Hyoung‐Mo Yang, So‐Yeon Choi, Seung‐Jea Tahk, Myeong‐Ho Yoon   +6 more
wiley   +1 more source

"RAL" the LDLR to lysosomes for degradation. [PDF]

Life Metab
Guan Y, Huang Y, Li Z, Wang Y.
europepmc   +1 more source

Triglyceride Polygenic Score Identifies Individuals Who May Respond Differently to Aspirin in Primary Prevention

Clinical Pharmacology &Therapeutics, EarlyView.
Low‐dose aspirin is no longer routinely recommended for the primary prevention of cardiovascular disease in older adults due to a lack of net benefit over bleeding risk. We hypothesized that genetic subgroups may experience differential harm or benefit from aspirin therapy.
Peter D. Fransquet, Chenglong Yu, Cammie Tran, Sultana Monira Hussain, Chad A. Bousman, Mark R. Nelson, Andrew M. Tonkin, John J. McNeil, Paul Lacaze   +8 more
wiley   +1 more source

Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation. [PDF]

Front Cardiovasc Med
Guan X, Li Z, Cheng H, Li J, Wen N, Wang L.   +5 more
europepmc   +1 more source